LASSUS, Johan, Etienne GAYAT, Christian MUELLER, Frank W. PEACOCK, Jindřich ŠPINAR, Veli-Pekka HARJOLA, Domingo PASCUAL-FIGAL, Said LARIBI, Damien LOGEART, Semir NOUIRA, Marco METRA, Roland von KIMMENADE, Atul PATHAK, Thomas MUELLER, Salvatore di SOMMA, Naoki SATO, Michael POTOCKI, Jiří PAŘENICA, Corinne COLLET, Alain COHEN-SOLAL, James L. Jr. JANUZZI a Alexandre MEBAZAA. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology. Clare: ELSEVIER IRELAND LTD, 2013, roč. 168, č. 3, s. 2186-2194. ISSN 0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2013.01.228.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study
Autoři LASSUS, Johan (246 Finsko), Etienne GAYAT (250 Francie), Christian MUELLER (756 Švýcarsko), Frank W. PEACOCK (840 Spojené státy), Jindřich ŠPINAR (203 Česká republika, garant, domácí), Veli-Pekka HARJOLA (246 Finsko), Domingo PASCUAL-FIGAL (724 Španělsko), Said LARIBI (250 Francie), Damien LOGEART (250 Francie), Semir NOUIRA (788 Tunisko), Marco METRA (380 Itálie), Roland von KIMMENADE (528 Nizozemské království), Atul PATHAK (250 Francie), Thomas MUELLER (40 Rakousko), Salvatore di SOMMA (380 Itálie), Naoki SATO (392 Japonsko), Michael POTOCKI (756 Švýcarsko), Jiří PAŘENICA (203 Česká republika, domácí), Corinne COLLET (250 Francie), Alain COHEN-SOLAL (250 Francie), James L. Jr. JANUZZI (840 Spojené státy) a Alexandre MEBAZAA (250 Francie).
Vydání International Journal of Cardiology, Clare, ELSEVIER IRELAND LTD, 2013, 0167-5273.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 6.175
Kód RIV RIV/00216224:14110/13:00070400
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ijcard.2013.01.228
UT WoS 000326184400077
Klíčová slova anglicky ADHF; Mortality; Risk prediction; Biomarkers; Reclassification
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 15. 4. 2014 16:33.
Anotace
Aim: This study aims to evaluate the incremental value of plasma biomarkers to traditional clinical variables for risk stratification of 30-day and one-year mortality in acutely decompensated heart failure (ADHF). Methods and results: Through an international collaborative network, individual patient data on 5306 patients hospitalized for ADHF were collected. The all-cause mortality rate was 11.7% at 30 days and 32.9% at one year. The clinical prediction model (age, gender, blood pressure on admission, estimated glomerular filtration rate <60mL/min/1.73 m(2), sodium and hemoglobin levels, and heart rate) had a c-statistic of 0.74 for 30-day mortality and 0.73 for one-year mortality. Several biomarkers measured at presentation improved risk stratification when added to the clinical model. At 30 days, the net reclassification improvement (NRI) was 28.7% for mid-regional adrenomedullin (MR-proADM; p<0.001) and 25.5% for soluble (s) ST2 (p<.001). At one year, sST2 (NRI 10.3%), MR-proADM (NRI 9.1%), amino-terminal pro-B-type natriuretic peptide (NT-proBNP; NRI 9.1%), mid-regional proatrial natriuretic peptide (MR-proANP; NRI 7.4%), B-type natriuretic peptide (NRI 5.5%) and C-reactive protein (CRP; NRI 5.3%) reclassified patients with ADHF (p<0.05 for all). CRP also markedly improved risk stratification of patients with ADHF as a dual biomarker combination with MR-proADM (NRI 36.8% [p<0.001] for death at 30 days) or with sST2 (NRI 20.3%; [p<0.001] for one-year mortality). Conclusion: In this study, biomarkers provided incremental value for risk stratification of ADHF patients. Biomarkers such as sST2, MR-proADM, natriuretic peptides and CRP, reflecting different pathophysiologic pathways, add prognostic value to clinical risk factors for predicting both short-term and one-year mortality in ADHF.
VytisknoutZobrazeno: 27. 4. 2024 02:07